Akkus G, Ulas B, Binokay H, Odabas F, Soysal R, Ozcan A
BMC Endocr Disord. 2025; 25(1):46.
PMID: 39972308
PMC: 11837582.
DOI: 10.1186/s12902-025-01875-7.
Parsons S, Wilson-Pogmore A, Sullivan T
Front Ophthalmol (Lausanne). 2024; 4:1388197.
PMID: 38984143
PMC: 11182225.
DOI: 10.3389/fopht.2024.1388197.
Wang D, Marous C, Celiker P, Deng W, Kristoferson E, Elsayed A
Front Ophthalmol (Lausanne). 2024; 3:1309850.
PMID: 38983053
PMC: 11182153.
DOI: 10.3389/fopht.2023.1309850.
Singh M, Rana N, Ahuja C, Gupta P, Zadeng Z
Indian J Ophthalmol. 2024; 72(6):844-848.
PMID: 38804801
PMC: 11232869.
DOI: 10.4103/IJO.IJO_1702_23.
Boynes A, Enright N, Hardy T, Khong J
Int Ophthalmol. 2024; 44(1):98.
PMID: 38376802
PMC: 10879244.
DOI: 10.1007/s10792-024-02934-z.
The evaluation of retrobulbar fat tissue in Graves' orbitopathy with shear-wave ultrasound elastography.
Gunes I, Yilmaz H, Onal E
Int Ophthalmol. 2024; 44(1):13.
PMID: 38321200
DOI: 10.1007/s10792-024-02962-9.
Choroidal thickness in thyroid eye disease and its correlation with disease activity.
Muralidhar A, Singh S, Das S, Mondal K, Kumar B, Agarwal M
Indian J Ophthalmol. 2023; 72(2):281-286.
PMID: 38146970
PMC: 10941914.
DOI: 10.4103/IJO.IJO_848_23.
Refractory Thyroid Eye Disease Unresponsive to Teprotumumab: A Case Report.
Singh G, Taylor B, Michalek S
Cureus. 2023; 15(11):e48861.
PMID: 38111423
PMC: 10727451.
DOI: 10.7759/cureus.48861.
Circulating miR-146a predicts glucocorticoid response in thyroid eye disease.
Manso J, Censi S, Clausi C, Piva I, Zhu Y, Mondin A
Eur Thyroid J. 2023; 12(5).
PMID: 37606076
PMC: 10563606.
DOI: 10.1530/ETJ-23-0083.
Factors Predicting Long-term Outcome and the Need for Surgery in Graves Orbitopathy: Extended Follow-up From the CIRTED Trial.
Taylor P, Rajendram R, Hanna S, Wilson V, Pell J, Li C
J Clin Endocrinol Metab. 2023; 108(10):2615-2625.
PMID: 36971324
PMC: 10505546.
DOI: 10.1210/clinem/dgad084.
Measuring Health-Related Quality of Life in Thyroid Eye Disease.
Sharma A, Stan M, Rootman D
J Clin Endocrinol Metab. 2022; 107(Suppl_1):S27-S35.
PMID: 36346683
PMC: 9359445.
DOI: 10.1210/clinem/dgac230.
Recent advances in graves ophthalmopathy medical therapy: a comprehensive literature review.
Li X, Li S, Fan W, Rokohl A, Ju S, Ju X
Int Ophthalmol. 2022; 43(4):1437-1449.
PMID: 36272013
PMC: 10113320.
DOI: 10.1007/s10792-022-02537-6.
Thyroid Eye Disease.
Szelog J, Swanson H, Sniegowski M, Lyon D
Mo Med. 2022; 119(4):343-350.
PMID: 36118816
PMC: 9462910.
Reduced choroidal peripapillary capillaries in thyroid-associated ophthalmopathy with early stage of dysthyroid optic neuropathy.
Wu J, Luo L, Zhou H, Wu Y, Zhang J, Cheng J
Int J Ophthalmol. 2022; 15(7):1135-1141.
PMID: 35919331
PMC: 9318097.
DOI: 10.18240/ijo.2022.07.14.
Update on thyroid eye disease: Regional variations in prevalence, diagnosis, and management.
Yu C, Ford R, Wester S, Shriver E
Indian J Ophthalmol. 2022; 70(7):2335-2345.
PMID: 35791115
PMC: 9426067.
DOI: 10.4103/ijo.IJO_3217_21.
Current concepts regarding Graves' orbitopathy.
Bartalena L, Tanda M
J Intern Med. 2022; 292(5):692-716.
PMID: 35604323
PMC: 9796560.
DOI: 10.1111/joim.13524.
Evaluation of Microcirculation in Optic Nerve Head Using Laser Speckle Flowgraphy in Active Thyroid Eye Disease.
Ho M, Tsai Y, Chu Y, Liao Y
Biomed Res Int. 2022; 2022:9115270.
PMID: 35342747
PMC: 8948602.
DOI: 10.1155/2022/9115270.
RAPD as a clinical alert for early evidence of dysthyroid optic neuropathy.
Gupta V, Das S, Mohan S, Chauhan U
J Family Med Prim Care. 2022; 11(1):370-375.
PMID: 35309667
PMC: 8930119.
DOI: 10.4103/jfmpc.jfmpc_1298_21.
Ocular surface disease in thyroid eye disease: A narrative review.
Rana H, Akella S, Clabeaux C, Skurski Z, Aakalu V
Ocul Surf. 2022; 24:67-73.
PMID: 35167950
PMC: 9058200.
DOI: 10.1016/j.jtos.2022.02.001.
Altered peripapillary vessel density and nerve fiber layer thickness in thyroid-associated ophthalmopathy using optical coherence tomography angiography.
Jian H, Wang Y, Ou L, He W
Int Ophthalmol. 2021; 42(3):855-862.
PMID: 34637060
PMC: 8917016.
DOI: 10.1007/s10792-021-02051-1.
